Neurotune expands its management by taking on an expert for preclinical development and appointing a new CFO
As the director of preclinical and clinical development, Dr. Jan Willem Vrijbloed will be responsible for the development of new medications. Dr Vrijbloed, was born in 1960 in the Netherlands and has more than 15 years of experience in preclinical and clinical development, as well as exploration of new substances in the field of cancer medication and antibiotics, plus research in organic chemistry and microbiology. Dr Vrijbloed acquired his diploma in biology and later his doctorate at the University of Groningen. After working at the University of Zurich and collaborating with Akzo-Nobel, Dr Vrijbloed joined Polyphor Ltd. in Switzerland in 2000, where he was initially Head of Biology and later Head of Development.
Michael Kregar, was born in 1970 in Switzerland, and is an expert with more than 15 years of experience as a manager of financial planning, controlling and revision, which he gained from different companies. His last post was as European Controller & Head of Finance in the Finance division of the Biolife Business Unit at Baxter Healthcare SA. He has also worked for Energis Carrier Services, PricewaterhouseCoopers und AT&T Corp in the UK and the US. Mr Kregar, is a certified public accountant in North Dakota, holds a Master of Business Administration from the Purdue University Krannert School of Management, and is currently completing his doctorate at the Manchester Business School of Manchester University in England.
Photos available on request.
Mrs. Theres Oesch
Assistant to the CEO
8952 Schlieren (Zurich)
Phone +41 44 200 21 95
Fax +41 44 200 20 10
Dr. Holger Bengs
Phone +49 (0)69 6199 4273
Fax: +49 (0)69 6199 4249
About Neurotune AG
Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.
Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for treatment of other CNS disturbances.
With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy –Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.
The treatment of Sarcopenia is a growing market with no available causal treatment.
* * * * *
This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotunes' shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotunes’ business, investors should consult Neurotune.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurotune expands its management by taking on an expert for preclinical development and appointing a new CFO here
News-ID: 25074 • Views: 1884
More Releases from Dr. Holger Bengs Biotech Consulting
IonGate starts commercialization of SURFE2R in Asia
Frankfurt/Main, Germany, March 12, 2008. IonGate Biosciences is expanding its operations to market the SURFE2R (SURFace Electrogenic Event Reader) Technology to the Japanese market. BRC - Bio Research Center Co. Ltd Nagoya, Japan and IonGate jointly introduce the proprietary technique to automatically screen transport proteins in high throughput at meetings in Japan, thus making the technology accessible to the Asian market. BRC is an established partner able to supply Japan’s researchers
IonGate presents SURFE2R Technology and relevant fields of application at Biophy …
Frankfurt/Main (Germany), January 28, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins at the 52nd Annual Meeting and 16th International Biophysics Congress. The joint meeting of the American Biophysical Society takes place in Long Beach, California, USA, on February 2 – 6, 2008. Scientists from industry, universities and private academic institutes use this opportunity to present results of their latest research
IonGate completes third funding round and expands its business to the USA
Frankfurt/Main (Germany), 16th January 2008. IonGate Biosciences GmbH announces the closing of the third funding round. The capital contribution of the investors Heidelberg Innovation and KfW (Kreditanstalt für Wiederaufbau) therewith amounts to €4.6 million in 2007. IonGate will use the increase in capital to expand its international business activities, for the worldwide commercialization of the SURFE2R Technology (SURFace Electrogenic Event Reader) and for the further development of the SURFE2R Workstation. In
Protagen raises €1 million to expand its protein biochips business unit
Dortmund, Germany and New Jersey, USA, 15 January 2008: Protagen AG, a leading provider of products, services and software solutions for protein research, announces the closing of an interim financing round. The €1 million raised will be used to expand the company’s protein biochips business unit. The capital raised in this round has come from the existing institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and S-Venture Capital Dortmund
More Releases for Neurotune
Neurotune starts Phase II Clinical Trial to treat neuropathic pain
Schlieren (Zurich), Switzerland, 17th August 2009. Neurotune AG, a Swiss biopharmaceutical company, has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication. Approximately 500.000 HIV-patients in the United States and Europe receive anti-retroviral medication. Neurotune’s Phase II trial (8-week, randomized, double-blind, placebo-controlled, parallel group study) will evaluate the safety
Change in the Management of Neurotune AG
Schlieren, 26th January 2009. Neurotune AG, a Swiss biopharmaceutical company, announces a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer from Dr. Andreas J. Schulze, who joined Neurotune in 2005 and is holding the position of CEO since 2006. Andreas J. Schulze will leave at his request to take on a fresh challenge in another company shortly. Bruno Oesch
Neurotune successfully completes Phase 1 Trials with its Lead Compound NT-11624
Schlieren, 15th January 2009. Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and ostheoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor. The studies on 56 healthy volunteers performed in Switzerland have demonstrated excellent tolerability
Neurotune expands its portfolio by acquiring
Schlieren, 18th September 2008. Neurotune AG, a Swiss biopharmaceutical company, announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of its portfolio with two programs in neuropathic pain. The company has reached an agreement with the Italy-based company Brane Discovery Srl. to acquire rights for two programs in neuropathic pain in a combined cash and share transaction. In a recent financing round, which was lead
Neurotune completes next funding round
Schlieren, 29th July 2008. Neurotune AG, a Swiss biopharmaceutical company, announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostical methods. Part of the capital will be used to extend a developmental pipeline. The company focuses on
Neurotune starts the preclinical development of initial candidate substances for …
Schlieren, 7th November 2007. Neurotune AG, a Swiss bio-pharmaceutical company, has moved to new laboratory and office facilities at the Biotech Centre in Zurich on 1st November 2007. This move is another step on the road to advance the development of Neurotune’s candidate substances for treating diseases of the human central and peripheral nervous system. Dr. Jan Willem Vrijbloed has been director of preclinical and clinical development since 1st August